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Abstract
The CmeABC multidrug efflux transporter of Campylobacter jejuni plays a key role in antimicrobial resistance
and is suppressed by CmeR, a transcriptional regulator of the TetR family. Overexpression of CmeABC has
been observed in laboratory-generated mutants, but it is unknown if this phenotype occurs naturally in C.
jejuni isolates and if it has any functional consequences. To answer these questions, expression of cmeABC in
natural isolates obtained from broiler chickens, turkeys and humans was examined, and the genetic
mechanisms and role of cmeABC differential expression in antimicrobial resistance was determined. Among
the 64 C. jejuni isolates examined in this study, 43 and 21 were phenotypically identified as overexpression
(OEL) and wild-type expression (WEL) levels. Representative mutations of thecmeABC promoter and/or
CmeR-coding sequence were analyzed using electrophoretic mobility shift assays and transcriptional fusion
assays. Reduced CmeR binding to the mutated cmeABCpromoter sequences or decreased CmeR levels
increased cmeABC expression. Several examined amino acid substitutions in CmeR did not affect its binding
to the cmeABC promoter, but a mutation that led to C-terminal truncation of CmeR abolished its DNA-
binding activity. Interestingly, some OEL isolates harbored no mutations in known regulatory elements,
suggesting that cmeABC is also regulated by unidentified mechanisms. Overexpression ofcmeABC did not
affect the susceptibility of C. jejuni to most tested antimicrobials except for chloramphenicol, but promoted
the emergence of ciprofloxacin-resistant mutants under antibiotic selection. These results link CmeABC
overexpression in natural C. jejuni isolates to various mutations and indicate that this phenotypic change
promotes the emergence of antibiotic-resistant mutants under selection pressure. Thus, differential expression
of CmeABC may facilitate Campylobacter adaptation to antibiotic treatments.
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Abstract
The CmeABCmultidrug efflux transporter of Campylobacter jejuni plays a key role in anti-
microbial resistance and is suppressed by CmeR, a transcriptional regulator of the TetR
family. Overexpression of CmeABC has been observed in laboratory-generated mutants,
but it is unknown if this phenotype occurs naturally in C. jejuni isolates and if it has any
functional consequences. To answer these questions, expression of cmeABC in natural
isolates obtained from broiler chickens, turkeys and humans was examined, and the
genetic mechanisms and role of cmeABC differential expression in antimicrobial resis-
tance was determined. Among the 64 C. jejuni isolates examined in this study, 43 and 21
were phenotypically identified as overexpression (OEL) and wild-type expression (WEL)
levels. Representative mutations of the cmeABC promoter and/or CmeR-coding sequence
were analyzed using electrophoretic mobility shift assays and transcriptional fusion
assays. Reduced CmeR binding to the mutated cmeABC promoter sequences or
decreased CmeR levels increased cmeABC expression. Several examined amino acid
substitutions in CmeR did not affect its binding to the cmeABC promoter, but a mutation
that led to C-terminal truncation of CmeR abolished its DNA-binding activity. Interestingly,
some OEL isolates harbored no mutations in known regulatory elements, suggesting that
cmeABC is also regulated by unidentified mechanisms. Overexpression of cmeABC did
not affect the susceptibility of C. jejuni to most tested antimicrobials except for chloram-
phenicol, but promoted the emergence of ciprofloxacin-resistant mutants under antibiotic
selection. These results link CmeABC overexpression in natural C. jejuni isolates to vari-
ous mutations and indicate that this phenotypic change promotes the emergence of antibi-
otic-resistant mutants under selection pressure. Thus, differential expression of CmeABC
may facilitate Campylobacter adaptation to antibiotic treatments.
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Introduction
Multidrug efflux pumps play key roles in bacterial physiology, conferring intrinsic and
acquired resistance to diverse toxic compounds. There are multiple types of drug efflux systems
in bacteria, but in gram-negative bacteria, the resistance-nodulation- cell division (RND) fam-
ily of efflux pumps is of primary importance for antimicrobial resistance [1]. ArcAB-TolC,
MexAB-OprM, and MexXY-Z in Escherichia coli and Pseudomonas aeruginosa are examples of
well-characterized RND efflux pumps that extrude bile salts, organic cations, detergents, and
various classes of antimicrobials [2–5]. These efflux pumps have been associated with intrinsic
and acquired resistance to antimicrobial compounds. CmeABC, also a member of the RND
family, is the predominant efflux pump in Campylobacter jejuni [6] and plays a key role in the
resistance to structurally diverse compounds, such as bile salts, ciprofloxacin, erythromycin,
ethidium bromide, and various detergents [6, 7]. Synergistic effects of CmeABC with other
resistance mechanisms (such as target gene mutations) contribute to high-level resistance to
macrolides, tetracyclines, and fluoroquinolones in Campylobacter [8–11]. Due to its significant
role in bile resistance, CmeABC is essential for Campylobacter colonization and adaptation in
the intestinal tract of animals [7].
CmeABC is comprised of an inner membrane transporter (CmeB), a periplasmic fusion
protein (CmeA), and an outer membrane protein (CmeC). The three components are encoded
by a three-gene operon [6]. Transcription of this operon is repressed by CmeR, a TetR family
transcriptional regulator [12]. The cmeR gene is located immediately upstream of the cmeABC
operon. The CmeR protein contains a C-terminal ligand-binding domain and a N-terminal
DNA-binding domain [7]. The DNA-binding domain interacts specifically with a 16-base
inverted repeat within the promoter region of the cmeABC operon [13]. This binding inhibits
the transcription of the cmeABC operon. However, mutation of CmeR or alteration of the pro-
moter sequences affects the binding of CmeR, resulting in increased expression of CmeABC
[12, 14]. Additionally, cmeABC expression is inducible by bile and this induction is through the
interaction of bile with the ligand-binding pocket of CmeR, which triggers a conformational
change in the DNA-binding domain, releasing CmeR from the cmeABC promoter [15, 16].
Gastroenteritis caused by Campylobacter is estimated to affect 845,024 people and cause
8,463 hospitalizations per year in the United States [17]. C. jejuni and C. coli are the most com-
mon Campylobacter species associated with foodborne disease and are commensals in avian
species (particularly poultry), swine, and ruminants [18]. Campylobacter contamination fre-
quently occurs with poultry meat and unprocessed milk. Thus, undercooked poultry and
unpasteurized milk are common vehicles for foodborne transmission of Campylobacter to
humans [18, 19]. Clinically, campylobacteriosis is manifested as diarrhea, abdominal cramps,
and fever, which typically resolves in 1 week without medical intervention. However, when
antimicrobial treatment is indicated with severe or prolonged cases, or in immunocompro-
mised patients, fluoroquinolones and macrolides are the drugs of choice [18, 20]. Increasing
resistance to these antibiotics in Campylobacter is problematic, especially to fluoroquinolones,
as Campylobacter is highly adaptable to fluoroquinolone treatment and acquisition of muta-
tions associated with fluoroquinolone resistance does not impose a fitness cost on this organ-
ism [21–23]. In all clinically relevant antibiotic resistance, CmeABC plays an important role as
inactivation of cmeABC rendered Campylobactermuch more susceptible to various antimicro-
bials [6].
Considering the significance of CmeABC in Campylobacter pathobiology, its varied expres-
sion levels are expected to affect antimicrobial resistance. Under toxic conditions or in the
adaptation to harsh environments, enhanced expression of cmeABCmay confer a survival
advantage on Campylobacter. The advantage may occur directly through increased extrusion
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of toxic substrates, which reduces their harmful effect and increased frequency of emergence of
antimicrobial resistant mutants. Although inactivation of cmeABC or overexpression of this
efflux pump has been examined under experimental conditions by using insertional mutagene-
sis or stepwise selection of mutants on antibiotic containing plates [12, 14], it is unknown if dif-
ferential expression of cmeABC occurs in naturally occurring isolates and if the differential
expression has any functional consequences. In this study, we investigated the expression of
cmeABC in C. jejuni isolates from turkeys, chickens, and humans, examined the mechanisms
associated with the differential expression, and measured the functional consequences associ-
ated with the differential expression.
Materials and Methods
Bacterial strains and growth conditions
Sixty-four naturally occurring Campylobacter isolates were originally derived from convention-
ally raised broiler chickens [24], conventionally raised turkeys [24], and clinical diarrheal cases
of humans [25]. These isolates were retrospective collections used in previous publications [24,
25]. The 20 broiler isolates, 17 turkey isolates, and 27 human isolates were confirmed to be C.
jejuni using the reportedmapA and 16S rRNA primers [26, 27]. Key PCR primers used in this
study are listed in Table 1. In addition to these isolates, several laboratory strains were also
used, including NCTC 11168 [28], 81–176 [29], 81–176ΔcmeR [12], 11168ΔcmeR [12] and the
quality control C. jejuni strain ATCC 33560 [30, 31], which are listed in Table 2. All strains
were routinely cultured in Mueller Hinton (MH) agar or MH broth (Difco, Detroit, MI) at
42°C under microaerobic conditions (5%O2, 10%CO2, 85%N2). Media were supplemented
with kanamycin at 30 μg/mL or chloramphenicol at 4 μg/mL when needed.
E. coli strains (Table 2) DH5α (Invitrogen), DH5αpMW10 [32], DH5αpRK2013 [33],
XL1-Blue (Agilent), and JM109 (Agilent) were cultured at 37°C. Luria-Bertani (LB) broth or
agar (Difco) was supplemented with 30 μg/mL of kanamycin or 100 μg/mL of ampicillin when
needed.
Immunoblotting
Isolates were initially screened for CmeABC expression by immunoblotting with polyclonal
antibodies against CmeABC. All clinical C. jejuni isolates, NCTC 11168 and 11168ΔcmeR were
cultured in MH broth. Samples were pelleted, and re-suspended in SDS loading buffer for a
final concentration of 5 x 109 CFU/mL. The protein samples were analyzed by SDS-PAGE and
immunoblotting as described previously using antibodies against CmeA, CmeB, CmeC [6] and
MOMP [9]. Bands for CmeA, CmeB, and CmeC from the clinical isolates were compared to
those of NCTC 11168 and 11168ΔcmeR by visual inspection and densitometric analysis using
the AlphaEaseFC Software (Version 3.2.3 Rev C; Innotech). Primary classification as wild type-
level (WEL) or overexpression level (OEL) of CmeABC was based on analysis of CmeB by den-
sitometry and CmeA was utilized as a secondary factor for the classification. The 64 clinical C.
jejuni isolates were analyzed on 8 immunoblots with NCTC 11168 and 11168ΔcmeR used as
controls for WEL and OEL, respectively. The threshold for CmeABC overexpression based on
densitometric analysis was a 2-fold increase for the CmeB band in relation to the expression
level in NCTC 11168. Each immunoblot was examined individually to ensure the threshold for
overexpression was met. This phenotypic classification was further confirmed by measuring
the cmeB transcript using real time RT- PCR. OEL isolates showed overexpression of CmeB on
immunoblotting and/or real time RT-PCR expression of cmeB. CmeA expression based on a
threshold of 2-fold for overexpression was used for isolates that remained between the two phe-
notypic groups after real time cmeB expression levels were analyzed.
Differential Expression of CmeABC
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The expression level of CmeR was also evaluated by immunoblotting in selected clinical iso-
lates that harbored mutations in the cmeR gene. The whole cell samples were prepared from
isolates M63885, CT9:7, CB2:6, CB2:8, CB2:11, S13530, T37957A, X7199, CT2:2, NCTC
11168, and 11168ΔcmeR. Samples were loaded onto a 12% SDS PAGE gel for electrophoresis
Table 1. Oligonucleotide primers used for PCR and real time RT-PCR.1
Primer Type Primer Name Sequence Source or Reference
PCR
RIGA2-F CAAGTTTAGCAGGGTAAGTAA This study
RIGA2-R TAAATTAAAAGCAGGAGAACAAG This study
16srRNA-F AATCTAATGGCTTAACCATTA [26]
16srRNA-R GTAACTAGTTTAGTATTCCGG [26]
mapA-F GAGTGCTTGTGCAACTAAAC [27]
mapA-R ATAGCATCTTGAGTTGCTCC [27]
GSF CTAAATGGAATCAATAGCTCC [12]
GSR1 GCACAACACCTAAAGCTAAAA [12]
PF AAAAGGATCCTAAATGGAATCAATAGCTCC (BamHI) [12]
PX GCGGCATTTGTATTTCTAGAGCTTCTTCT (XbaI) This study
pMW10-F ATCTGCCTCCTCATCCTCTTCAT This study
pMW10-R ATTCAGGCTGCGCAACTGTT This study
M63R17-F ATGAACTCAAATAGAATACCATCACAAAAAGTT This study
M63R17-R AACTTTTTGTGATGGTATTCTATTTGAGTTCAT This study
M63R475-F TATATGAAAAAAAATGCAAAAAAACTTGCTGTTCTTT This study
M63R456-R AAAGAACAGCAAGTTTTTTTGCATTTTTTTTCATATA This study
T3X250A-F CCAAAACACAAGAAATTAAAAATGGCACTTTAAAA This study
T3X250A-R TTTTAAAGTGCCATTTTTAATTTCTTGTGTTTTGG This study
T97547G-F AATGTTTTAATTAACGCTGCTTTGAAAAATAAAAAAG This study
T97547G-R CTTTTTTATTTTTCAAAGCAGCGTTAATTAAAACATT This study
T22583-F1 GAACATGTTTGAATTTGTTGTAAATGTTTTT This study
T22583-R1 AAAAACATTTACAACAAATTCAAACATGTTC This study
r431GA-F CTATAACATACTTATGGATTTTTTCAAGCAACAAA This study
r431GA-R TTTGTTGCTTGAAAAAATCCATAAGTATGTTATAG This study
r619621-F AATGGAATCAATGGATCCAAAGCTTAA This study
r619621-R TTAAGCTTTGGATCCATTGATTCCATT This study
pQETypeIII/I-F CG GATAACAATT TCACACA G Promega
pQEReverse-R GTTCTGAGGTCATTACTGG Promega
Cj0370-F1 CAGTCCTCACCACCTTTCT This study
Cj0368c-R AGGCCACTGCTTTGATT This study
370BamH-F CAGTCGGATCCACCTTTC (BamHI) This study
369XbaI-R1 AAATATCGTTTTTTTCTAGAGTTTGTAAT (XbaI) This study
Real time RT-PCR
16S-F TACCTGGGCTTGATATCCTA [34]
16S-R GGACTTAACCCAACATCTCA [34]
cmeB-F ACGATTCAACCTTTTCCCAGC [34]
cmeB-R TTTGCTACTTGAGCAATCGCTTC [34]
F3 ATTTTCAATCAACCAGAAGCTG [16]
R3 TCCAATTGGCAAGATGTCTATC [16]
1 Restriction sites are indicated by underlined sequence
doi:10.1371/journal.pone.0131534.t001
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Table 2. Bacterial strains or plasmids used in this study.
Plasmid or Bacteria Plasmid or Strain
Name
Description Source
Plasmids
pMW10 E. coli–Campylobacter shuttle vector carrying promoter-less lacZ, KanR [32]
pMW11168 pMW10 carrying the cmeABC promoter from NCTC11168 fused to lacZ, KanR This
study
pMW81-176 pMW10 carrying the cmeABC promoter from 81–176 fused to lacZ, KanR This
study
pMWX7199 pMW10 carrying the cmeABC promoter from X7199 fused to lacZ, KanR This
study
pMWM32506 pMW10 carrying the cmeABC promoter from isolate M32506 fused to lacZ, KanR This
study
pMW1:1 pMW10 carrying the cmeABC promoter from isolate CT1:1 fused to lacZ, KanR This
study
pMW1:9 pMW10 carrying the cmeABC promoter from isolate CT1:9 fused to lacZ, KanR This
study
pMW3:7 pMW10 carrying the cmeABC promoter from isolate CT3:7 fused to lacZ, KanR This
study
pMW9:20 pMW10 carrying the cmeABC promoter from isolate CT9:20 fused to lacZ, KanR This
study
pMW11168-R pMW10 carrying the Cj0369c-cmeR promoter from NCTC 11168 fused to lacZ, KanR This
study
pMW81-176-R pMW10 carrying the Cj0369c-cmeR promoter from 81–176 fused to lacZ, KanR This
study
pMWX7199-R pMW10 carrying the Cj0369c-cmeR promoter from isolate X7199 fused to lacZ, KanR This
study
pQE30 Expression vector for N-terminal 6-His tagged proteins, AmpR Qiagen
pQECmeRSS pQE30 carrying CmeR with the C69S and C166S mutations [37]
pQECmeR-K pQE30 carrying CmeRSS with the E84K mutation, AmpR This
study
pQECmeR-R pQE30 carrying CmeRSS with the P183R mutation, AmpR This
study
pQECmeR-IK pQE30 carrying CmeRSS with the T6I and E159K mutations, AmpR This
study
pQECmeR-tr pQE30 carrying CmeRSS with the G144A and S207G amino acid mutations. Also
carries T insertion at nucleotide 583 causing frame shift after amino acid 193, AmpR
This
study
Campylobacter jejuni
strains
NCTC 11168 Wild type; genome sequence known [1]
11168ΔcmeR Derivative of NCTC 11168, cmeR::cat [2]
ATCC 33560 C. jejuni quality control strain [3, 4]
81–176 Wild type; isolated from a human [5]
81-176pMW10 Derivative of 81–176 carrying pMW10 This
study
81-176pMW11168 Derivative of 81–176 carrying pMW11168 This
study
81-176pMW81-176 Derivative of 81–176 carrying pMW81-176 This
study
81-176pMWX7199 Derivative of 81–176 carrying pMWX7199 This
study
81-176pMWM32506 Derivative of 81–176 carrying pMWM32506 This
study
(Continued)
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Table 2. (Continued)
Plasmid or Bacteria Plasmid or Strain
Name
Description Source
81–176 pMW1:1 Derivative of 81–176 carrying pMW1:1 This
study
81–176 pMW1:9 Derivative of 81–176 carrying pMW1:9 This
study
81–176 pMW3:7 Derivative of 81–176 carrying pMW3:7 This
study
81–176 pMW9:20 Derivative of 81–176 carrying pMW9:20 This
study
81–176ΔcmeR Derivative of 81–176, cmeR::cat [2]
81–176ΔcmeR pMW10 Derivative of 81–176ΔcmeR carrying pMW10 This
study
81–176ΔcmeR
pMW11168
Derivative of 81–176ΔcmeR carrying pMW11168 This
study
81–176ΔcmeR pMW81-
176
Derivative of 81–176, cmeR::cat carrying pMW81-176 This
study
81–176ΔcmeR
pMWX7199
Derivative of 81–176ΔcmeR carrying pMWX7199 This
study
81–176ΔcmeR
pMWM32506
Derivative of 81–176ΔcmeR carrying pMWM32506 This
study
81–176ΔcmeR pMW1:1 Derivative of 81–176ΔcmeR carrying pMW1:1 This
study
81–176ΔcmeR pMW1:9 Derivative of 81–176ΔcmeR carrying pMW1:9 This
study
81–176ΔcmeR pMW3:7 Derivative of 81–176ΔcmeR carrying pMW3:7 This
study
81–176ΔcmeR
pMW9:20
Derivative of 81–176ΔcmeR carrying pMW9:20 This
study
81-176pMW11168-R Derivative of 81–176 carrying pMW11168-R This
study
81-176pMW81-176-R Derivative of 81–176 carrying pMW81-176-R This
study
81-176pMWX7199-R Derivative of 81–176 carrying pMWX7199-R This
study
Escherichia coli
strains
DH5α F-Φ80lacZΔM15 Δ(lacZYA-argF) U169 recA1 endA1 hsdR17 (tκ,-mκ+) phoA supE44λ-
thi-1 gyrA96 relA1
Invitrogen
DH5αpRK2013 IncP KmR Tra RK2+ ΔrepRK2 repE1+ [6]
DH5αpMW10 DH5α derivative carrying pMW10 [7]
JM109 e14-(McrA-) recA1 endA1 gyrA96 thi-1 hsdR17(tκ-mκ+) supE44 relA1 Δ(lac-proAB) [F’
traD36 proAB lacqZΔM15]
Agilent
XL-1 Blue recA1 endA1 gyrA96 thi-1 hsdR17 supE44 relA1 lac [F’ proAB lacIqZΔM15 Tn10 (Tetr) Agilent
JM109pQECmeRSS Derivative of JM109 carrying pQECmeRSS AmpR [1]
JM109pQECmeR-R Derivative of JM109 carrying pQECmeR-R, AmpR This
study
JM109pQECmeR-IK Derivative of JM109 carrying pQECmeR-IK, AmpR This
study
XL1-Blue pQECmeR-tr Derivative of XL1-Blue carrying pQECmeR-tr, AmpR This
study
doi:10.1371/journal.pone.0131534.t002
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in Lameilli buffer at 80V for 30 minutes followed by 200V for 60 minutes. The gel and PVDF
membrane were equilibrated in Towbin transfer buffer for 30 minutes, assembled onto the
transfer apparatus, and transferred at 60 V for 40 minutes in Towbin transfer buffer. The mem-
brane was blocked in blocking buffer (5% skim milk with 0.01% Tween-20 in PBS) at 4°C on a
rocker. Then it was incubated with rabbit anti-CmeR diluted 1:100 in blocking buffer for 90
minutes at room temperature on a rocker. The membrane was washed 3 times for 10 minutes
in washing buffer (0.01% Tween-20 in PBS) and further incubated with goat anti-rabbit IgG
conjugated with horseradish peroxidase (KPL) (1:1000 in blocking buffer) for 1 hour at room
temperature. After three washings, the membrane was developed with the 4CN Horseradish
Peroxidase Substrate system (KPL). Densitometric analysis for CmeR was performed in the
same manner for CmeABC.
SDS-PAGE and immunoblotting were also performed for the recombinant mutant CmeR
named rCmeR-tr to determine if the protein was recognizable by CmeR antibodies. This
recombinant protein was derived from mutations in strain CT2:2 (Table 3). The recombinant
CmeR named rCmeRSS was used as a control. Both rCmeRSS and rCmeR-tr were loaded at
400 ng onto a 12% SDS-PAGE gel. Electrophoresis and immunoblotting were performed using
the same methods used for immunoblotting of CmeR in clinical isolates.
Real time RT-PCR
Transcription of cmeB and cmeR was detected by real time RT-PCR to confirm the results of
immunoblotting. RNA was isolated from 24-hour cultures of clinical isolates, NCTC 11168,
and 11168ΔcmeR as described previously (13). Real time RT-PCR was performed for all isolates
for cmeB and for selected isolates for cmeR as described previously (12, 13, 16, 34). The primers
used for real time RT-PCR are shown in Table 1. Relative expression based on NCTC 11168
was calculated with the Pfaffl Method [35]. Overexpression of cmeB was defined as greater or
equal to 3 fold of NCTC 11168 expression. cmeB expression measured by RT-PCR was com-
pared with the result of immunoblotting for final determination of a CmeABC phenotype. For
Table 3. Mutation, expression, and phenotypes of CmeR in selectedC. jejuni isolates.
Clinical
Isolate
cmeR Expression Fold
Change*
Nucleotide
Mutation
Amino Acid
Mutation
Recombinant
Protein
Binding to cmeABC
promoter
CT2:2 0.006 G431A G144A rCmeR-tr No
583 T insertion Truncation after 193
A619G S207G
C621A Silent
M63885 0.845 C17T T6I rCmeR-IK Yes
G475A E159K
T37957A 33.107 G250A E84K rCmeR-K Yes
CT9:7 0.378 C547G P183R rCmeR-R Yes
CB2:8 1.117 G431A G144A Not tested Not tested
CB2:11 0.327 C547G P183R
CB2:6** 0.806 A619G S207G
S13530 0.184 C621A silent
X7199 10.861 None None Not tested Not tested
*In relative to the expression level in NCTC 11168 as determined by RT-PCR
**Isolate is phenotypically classiﬁed as WEL
doi:10.1371/journal.pone.0131534.t003
Differential Expression of CmeABC
PLOSONE | DOI:10.1371/journal.pone.0131534 July 1, 2015 7 / 26
those isolates where RT-PCR and immunoblotting data did not align, less weight was given to
real time RT-PCR data due to reported variability in cmeB coding sequence [36].
DNA sequencing
DNA sequencing was performed to determine if isolates were carrying mutations in cmeR, the
Cj0369c-cmeR promoter or the cmeABC promoter. All clinical isolates classified as having a
phenotype of CmeABC overexpression, some selected clinical isolates with the wild-type
expression levels, and 81–176 were amplified with RIGA-F and RIGA-R primers (Table 1) for
sequence analysis of the region between cmeR to the 5’end of cmeA, which covers the whole
ORF of cmeR and the entire promoter of cmeABC. Additionally, the predicted promoter region
of Cj0369c-cmeR (the two genes share a single promoter located upstream of Cj0369c) was
examined to determine if mutations in the promoter region were involved in differential CmeR
expression in clinical isolates. The Cj0369c-cmeR promoter was amplified with Cj0370-F and
Cj0368c-R (Table 1). GenBank accession numbers are found in S1 Table.
Electrophoretic mobility shift assays (EMSA)
EMSA was used to assess the binding of CmeR to the cmeABC promoter sequences from vari-
ous clinical isolates. These clinical isolates were observed to contain sequence polymorphisms
within the cmeABC promoter region. A recombinant CmeR named rCmeRSS [37] with cyste-
ines 69 and 166 replaced with serine was used for EMSA as described previously [12, 38]. The
Cys-Ser substitution does not affect the binding activity, but significantly improves the stability
of recombinant CmeR as the Cys residues are sensitive to oxidation during in vitro binding
assay. The 170-bp cmeABC promoter sequences were amplified from genomic DNA of NCTC
11168, 81–176, CT3:7, CT1:1, CT1:9, CT9:20, and X7199 with primers GSF and GSR1[12]
(Table 1). The amplified products were purified (QIAquick PCR Purification kit, Qiagen) and
then labeled with DIG-11-dd-dUTP using the DIG Oligonucleotide 3’ End Labeling kit
(Roche). The labeled promoter DNA was used as probes in EMSA.
The cmeABC promoter probes were named for their strain of origin: 11168, 81–176, CT3:7,
CT1:1, CT1:9, CT9:20 and X7199. Promoter probes from clinical isolates (CT3:7, CT1:1,
CT1:9, CT9:20 and X7199) were compared with the promoter probes of 11168 or 81–176 (lab-
oratory strains), depending on their similarity to the CmeR binding site in the two laboratory
strains. The CmeR-binding site contains an A to T substitution in the 81–176 strain compared
to 11168, which is considered a naturally occurring variation [12].
The promoter probes (0.05 pmol each) were incubated with 0, 60, 120, and 180 ng of
rCmeRSS in 22 μL of binding buffer according to the method of Alekshun et. al. and Lin et. al.
2005 [12, 38]. The reaction mixtures were incubated for 30 minutes at room temperature and
Promega DNA loading buffer was added to each reaction. Samples were separated by electro-
phoresis at 200V for 45 minutes on a 6% polyacrylamide gel in 0.25X TBE Buffer and trans-
ferred to a positively charged nylon membrane by vacuum [12]. Chemiluminescent detection
using alkaline phosphatase-conjugated anti-DIG antibody and CDP-Star (Roche) was per-
formed as previously described [12].
Construction of promoter fusions and β-galactosidase assays
The observed sequence polymorphisms in the promoter sequences of cmeABC were assessed
for their impact on cmeABC transcription by constructing transcriptional fusions with a pro-
moter-less lacZ gene. Genomic DNA templates (NCTC 11168, 81–176, CT1:1, CT 1:9, CT9:20,
CT3:7, M32506 and X7199) were used for amplification of a 578-bp sequence containing the
cmeABC promoter with primers PF [12] and PX (Table 1). These PCR products were purified
Differential Expression of CmeABC
PLOSONE | DOI:10.1371/journal.pone.0131534 July 1, 2015 8 / 26
(QIAquick PCR Purification kit), digested with XbaI and BamHI (Promega), and re-purified
using the QIAquick kit. Vector pMW10 [32] was purified (QIAprep Spin Miniprep kit, Qia-
gen) from DH5αpMW10 (Table 2), digested with the same enzymes, and re-purified. Vector
and PCR product inserts were ligated with T4 ligase (Roche) and transformed into DH5α.
Transformants were selected on LB agar plates supplemented with kanamycin (30 μg/mL).
Plasmid constructs (Table 2) were purified from DH5α and sequenced with pMW10-F and
pMW10-R (Table 1) to confirm the appropriate sequences and fusion.
To transfer the plasmids into C. jejuni, tri-parental mating using C. jejuni 81–176, E. coli
DH5αpRK2013 [33], and the various DH5α pMW10 transcriptional fusion constructs was per-
formed as described previously [33]. After transfer into C. jejuni 81–176, plasmids
pMW11168, pMW81-176, pMW1:1, pMW1:9, pMW3:7, pMW9:20, pMWM32506, and
pMWX7199 (Table 2) were purified and electroporated into 81–176ΔcmeR. The empty vector,
pMW10, was also transferred to 81–176 and 81–176ΔcmeR by the same methods and used as a
background control. Cultures were grown for 20 hours in MH broth supplemented with kana-
mycin (30 μg/mL), then β-galactosidase assays were performed as described previously [39].
Three independent experiments were conducted. Student’s t-test with Welch’s correction was
used to compare the expression data from various promoters and was done using GraphPad
InStat (Version 3.06) with the significance level set at 0.05.
Sequence polymorphisms were also observed in the Cj0369c-cmeR promoter. To determine
if these mutations affected CmeR expression, a second set of promoter fusions was created
using the same method. Briefly, primers 370BamH-F and 369XbaI-R1 (Table 1) were used to
amplify a 238-base pair segment containing the Cj0369c-cmeR promoter from genomic DNA
templates of NCTC 11168, 81–176 and X7199. Construction of plasmids, transformation into
DH5α and sequencing was performed as described above. Plasmid constructs pMW11168-R,
pMW81-176-R and pMWX7199-R were electroporated into C. jejuni 81–176 (Table 2). The
empty vector, 81-176pMW10, from the prior assay was used as a background control. β-galac-
tosidase assays for 3 independent experiments and statistical analysis were performed as
described in the assays with the cmeABC promoters.
Construction, purification, and functional analysis of various CmeR
variants
Sequence polymorphisms were detected in CmeR among the analyzed isolates. To determine if
the sequence variations affected the DNA binding activity of CmeR, we generated various
forms of recombinant CmeR using site-directed mutagenesis. Plasmid pQECmeRSS [37] was
used as a template for site directed mutagenesis, which was done using the Stratagene Quik-
Change II kit. Site-specific primers (Table 1) were used to produce the amino acid changes in
CmeR from isolates CT2:2, M63885, CT9:7, and T37597A. All amino acid substitutions, corre-
sponding nucleotide sequences and protein names are listed in Table 3. Isolate M63885 con-
tains 2 amino acid substitutions in CmeR, which were introduced simultaneously into the
pQECmeRSS template. The M63R17-F and M63R17-R primers were used to mutate the threo-
nine to isoleucine at residue 3 and the M63475-F and M63475-R primers were used to mutate
the glutamate to lysine at residue 159. This mutated plasmid was named pQECmeR-IK. Iso-
lates CT9:7 and T37957A both contain a single amino acid substitution in CmeR. Primers
T97547G-F and T97547G-R were used to change the proline to arginine at residue 159 as
observed in strain CT9:7, creating the plasmid named pQECmeR-R. Primers T3X250A-F and
T3X250A-R introduced the glutamate to lysine substitution at residue 84 as observed in strain
T37957A. This plasmid was named pQECmeR-K. Isolate CT2:2 contains 2 amino acid substi-
tutions in CmeR and a nucleotide insertion. This mutated CmeR was created using 2 rounds of
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mutagenesis. The T insertion after nucleotide 583 was introduced into template pQECmeRSS
with primers T22583-F1 and T22583-R1 along with the first amino acid substitution at residue
144, a glycine to alanine substitution, with primers r431GA-F and r431GA-R to create an inter-
mediate plasmid. The mutations were confirmed in the intermediate plasmid prior to introduc-
tion of the final mutations. In the second round of mutagenesis, this intermediate was used as a
template to introduce the final amino acid change, a serine to glycine substitution at residue
207 with primers r619621-F and r619621-R to create plasmid pQECmeR-tr.
All mutations were introduced into the respective templates by one cycle of 95°C for 30 sec-
onds followed by 16 cycles of 95°C for 30 seconds, 55°C for 30 seconds, and 68°C for 4 minutes.
The amplified product was cooled on ice for 2 minutes before Dpn-I digestion of parental
DNA at 37°C for 1 hour. Each product was transformed into JM109 or XL1-Blue (Agilent) and
the transformants were selected on LB agar supplemented with ampicillin (100 μg/mL). The
specific mutations were confirmed by sequencing with primers pQETypeIII/IV-F and pQERe-
verse-R (Table 1).
The CmeR variants including rCmeR-tr, rCmeR-R, rCmeR-K, and rCmeR-IK were induced
and purified from their respective E. coli strains (Table 2) under native conditions [40]. After
purification, proteins were desalted using PD-10 desalting columns (GE Healthcare). Proteins
of rCmeR-tr and rCmeR-K were concentrated in PBS using Amicon Centricon YM-10 Col-
umns (Millipore).
For functional analysis, EMSA was used to assess the ability of the mutated versions of
CmeR to bind to the cmeABC promoter. Binding by the purified mutant proteins rCmeR-tr,
rCmeR-R, rCmeR-K or rCmeR-IK was compared to binding by the rCmeRSS protein. The
11168 cmeABC promoter probe (0.05 pmol) was incubated with 0, 60, 120, and 180 ng of
rCmeRSS or one of the mutant rCmeR proteins in 22μL of reaction buffer according to the
method of Alekshun et. al. and Lin et. al. 2005 [12, 38]. The reaction mixtures were incubated
for 30 minutes at room temperature and Promega DNA loading buffer was added to each reac-
tion. Electrophoresis, transfer, and detection were performed using the same methods as
described for the EMSA assay.
Antimicrobial susceptibility testing
Agar dilution test was performed in MH agar and MH agar supplemented with 12,500 μg/mL
of sodium choleate according to the CLSI-recommended method [31]. Ciprofloxacin, kana-
mycin, erythromycin, tetracycline, ampicillin, clindamycin, chloramphenicol, ethidium bro-
mide, sodium choleate, cholic acid and taurocholic acid were tested. In addition to the 21
WEL and 43 OEL clinical isolates, 3 laboratory strains classified as WEL isolates, NCTC
11168, ATCC33560, and 81–176, were also tested. At least 2 experiments were performed for
each isolate. Distribution of the minimum inhibitory concentration (MIC) around the
median was tested with the Brown Forsythe test (SAS version 9.2) comparing the 43 OEL and
24 WEL isolates. The significance level set at 0.05.
Fluctuation assays
Fluctuation assays were performed to assess if CmeABC expression levels affected the sponta-
neous mutation rate to ciprofloxacin in C. jejuni. The assays were conducted using the methods
described by Luria and Delbrück [41] with some modifications [42–46]. Selected WEL isolates
(NCTC 11168, 81–176, CB8:14, CT10:18, H2958, CB6:8) and OEL isolates (CT9:7, CB4:22,
M76297, CT9:14, CB3:1, T37957A, 11168ΔcmeR, 81–176ΔcmeR) were cultured on antimicro-
bial-free MH plates, adjusted to 108 CFU/mL in MH broth, and serially diluted to 104. Thirty-
six parallel cultures of 200 μL were inoculated on a 96-well plate and incubated for 24 hours.
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Total cell counts were determined by plating on antimicrobial free MH agar while spontaneous
mutant counts were plated on MH agar supplemented with 4 μg/mL of ciprofloxacin.
Total cell counts for each set of cultures (36 parallel cultures) were estimated from 5 random
wells. The 5 wells were selected using the Random Integer Set Generator (Random.org). From
each of these wells, a 10 μL sample of culture was removed and serially diluted to 10−7. A 90 μL
sample from the 10−5, 10−6, and 10−7 dilutions was spread to MH agar. Plates were incubated
for 2 days for total CFU counts. Counts from the 5 random wells were averaged to determine
the total count for each set of 36 parallel cultures.
To determine the number of spontaneous mutants, all 36 wells were plated to MH agar con-
taining 4 μg/mL of ciprofloxacin. Plates were checked after 2 days for colony size and incubated
for an additional day to ensure colonies were large enough for counting. Mutation rate was cal-
culated by the Ma-Sandri-Sarkar Maximum Likelihood Estimator method using the Fluctua-
tion Analysis Calculator [47]. Mutations per culture (m) for WEL and OEL were transformed
by the natural logarithm (ln(m)) and compared with the Student’s t-test using GraphPad InStat
(Version 3.06) with the significance level set at 0.05.
In vitro ciprofloxacin treatment
Inactivation of CmeABC reduced the emergence of ciprofloxacin-resistant mutants in C. jejuni
under antibiotic selection, while inactivation of cmeR (resulting in overexpression of cmeABC)
increased mutant emergence, suggesting that expression levels of CmeABC influences the
emergence of antibiotic resistant mutants. To assess if differential expression of cmeABC in
naturally occurring isolates affects their adaptation to antibiotic treatment, we examined the
emergence frequencies of ciprofloxacin-resistant mutants in isolates of different CmeABC phe-
notypes. Three WEL (CB6:8, F15871, CT10:18) and three OEL isolates (T37957A, CT7:20,
CB8:14) were used for this experiment, which were cultured on non-selective media (MH agar)
and then treated with 4 μg/mL of ciprofloxacin using the method of Han et. al. 2008 [48] with
some modifications. Briefly, MH broth supplemented with 4 μg/mL of ciprofloxacin was inoc-
ulated to an initial concentration of 107 CFU/mL in a 20 mL of culture with 3 replicates per iso-
late. Cultures were incubated for 3 days. Samples (0.5 mL) were taken on days 0, 1, 2, and 3—
post inoculation for enumeration of ciprofloxacin-resistant mutant and total cell counts. Total
counts were cultured on MH agar according to the plate drop method [49] for days 0, 1, 2, and
3. For days 0 to 2 mutants were counted by direct plating 100 μL of culture onto MH-ciproflox-
acin (4 μg/mL) agar in duplicate and according to the plate drop method [49] onto MH-cipro-
floxacin (4 μg/mL) agar. For day 3, total plate counts and mutants were all determined by the
plate drop method. The serial dilutions used in the plate drop method were dilutions 10−2 to
10−7 for day 0 and 10−3 to 10−8 for days 1 to 3. Two independent experiments were performed
for each isolate. The cell counts were calculated for each culture and log transformed. Data
analysis was performed with Graph Pad Prism (Version 6.0c) with multiple unpaired t-tests
and Holm-Šídák method for multiple comparisons. The significance level was set at 0.05.
In the second experiment, cultures were inoculated to an initial density of 106 CFU/mL.
Samples were collected in the same manner as the first experiment. For each day total counts
were cultured on MH agar according to the plate drop method [49]. Mutants were counted by
direct of plating 100 μL of culture to MH-ciprofloxacin (4 μg/mL) agar in duplicate and serial
dilutions for plate drop method [49] onto MH-ciprofloxacin (4 μg/mL) agar. The serial dilu-
tions used in the plate drop method were dilutions 10−2 to 10−7 for day 0 and 10−3 to 10−8 for
days 1 to 3. Two independent experiments were performed for each isolate. Data analysis was
performed as described in the prior experiment.
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Results
Phenotypic classification of isolates
Initial screening for phenotypic classification of CmeABC expression was done through immu-
noblotting (Fig 1) and real time RT-PCR for expression of cmeB. Analysis of the 64 C. jejuni iso-
lates for cmeB expression identified 43 isolates with overexpression levels (OEL) of CmeABC
and 21 isolates with wild-type expression levels (WEL) of CmeABC. The region spanning from
cmeR to cmeA was sequenced for all OEL isolates, 4 of theWEL isolates, and C. jejuni strain
81–176 to identify genetic mutations that were potentially associated with the differential
cmeABC expression (S1 Table). All isolates except 1 OEL isolate harbored mutations in the
sequenced region compared to the same region in strain NCTC 11168.
To refine the identification of mutations mediating differential cmeABC expression, the
cmeABC promoter was analyzed for mutations unique to the OEL isolates and cmeR was ana-
lyzed for DNA polymorphisms resulting in amino acid changes. The CmeR binding site of the
cmeABC promoter contains an A to T substitution at base 10 of the 16 base inverted repeat in
strain 81–176 (Fig 2A) that is considered a natural variation (81–176 variation) [6]. Among the
clinical isolates, 34 carried this mutation. Isolates that contained only the 81–176 variation in
the CmeR binding site were excluded from further analysis. There were 14 OEL isolates carry-
ing mutations within the CmeR binding site of the cmeABC promoter other than the 81–176 A
to T substitution (Fig 2A). These isolates also carried amino acid mutations in CmeR. All of the
observed amino acid mutations were also seen in isolates with no mutations in the cmeABC
promoter. These 14 isolates were categorized as cmeABC promoter mutants.
Analysis of cmeR for DNA polymorphisms found numerous mutations leading to amino
acid changes in CmeR. DNA polymorphisms that did not result in amino acid changes in
Fig 1. Differential expression of CmeABC in clinicalCampylobacter jejuni isolates. Expression was determined by immunoblotting of whole cell
proteins from NCTC 11168 (lane 1), clinical isolates (lanes 2–11), and 11168ΔcmeR (lane 12) with anti-CmeB, anti-CmeC, anti-CmeA, and anti-major outer
membrane protein (MOMP) antibodies. These broiler isolates in lanes 2 to 11 are CB1:6, CB1:14, CB 1:18, CB2:6, CB2:8, CB2:11, CB3:1, CB3:5, CB 3:14,
and CB3:21. Isolates CB2:8, CB2:11, CB 3:1, CB3:5, CB3:14 and CB3:21 (lanes 6–11) were designated as having overexpression levels of CmeABC and
isolates CB1:6, CB1:14, CB 1:18, and CB2:6 (lanes 2–5) as having wild-type levels of CmeABC. The major outer membrane protein (MOMP) was used as an
internal control.
doi:10.1371/journal.pone.0131534.g001
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CmeR were excluded. Three isolates, M63885, T37957A, and CT9:7 harbored unique muta-
tions in CmeR (Table 3). Other OEL isolates carried amino acid changes in CmeR that were
also seen in WEL isolates. Five OEL isolates and one WEL isolate with a unique combination
of substitutions at residues 144, 183 and 207 were also selected for analysis (Table 3). None of
these isolates, except X7199, had mutations in the cmeABC promoter. Together these 9 clinical
isolates were categorized as cmeRmutants.
Mutation of the CmeR binding site affects cmeABC expression in clinical
isolates
Fig 2A illustrates the region of the cmeABC promoter containing the CmeR binding site. Two
categories of substitutions were observed in the CmeR binding site: 5 isolates with a G to A
Fig 2. Binding of CmeR to variants of the cmeABC promoter in different isolates. (A) Sequence alignment of the cmeABC promoter region illustrating
the 16-base inverted repeat of the CmeR binding site shown in lowercase letters. The strain names are listed on the left of each sequence. All mutations
differing from the 11168 promoter are highlighted in bold. (-) indicates a deleted base. (B) EMSA showing the binding of rCmeRSS to different promoter
variants. The control probes include the NCTC 11168 probe (lanes 1–4) in panels I-III and the 81–176 probe (lanes 1–4) in panels IV to VI. The variant
promoter probes include CT1:1 (panel I, lanes 5–8), CT1:9 (panel II, lanes 5–8), M32506 (panel III, lanes 5–8), X7199 (panel IV, lanes 5–8), CT3:7 (panel V,
lanes 5–8), and CT9:20 (panel VI, lanes 5–8). For each probe, the amount of rCmeRSS used for the each reaction was 0 (lanes 1 and 5), 60 (lanes 2 and 6),
120 (lanes 3 and 7), and 180 ng (lanes 4 and 8), respectively. The rCmeRSS-DNA complexes are indicated with a “C” and the unbound promoter probe is
indicated with a “P”.
doi:10.1371/journal.pone.0131534.g002
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substitution at base 2 of the inverted repeat and 7 isolates with an A to G substitution at base
14. The 81–176 variation (A to T at base 10) is found in 7 isolates carrying the substitution at
base 14 and one isolate carrying the substitution at base 2. Two isolates carrying the 81–176
variation and a 5 base deletion in the cmeABC promoter were detected. The last 3 bases of the
CmeR binding site and the following 2 bases are absent in isolate CT9:20 (Fig 2A). Isolate
X7199 has a 5 base deletion 5’ to the CmeR binding site in addition to an A to G substitution at
base 14 of the CmeR binding site (Fig 2A). These 14 isolates are considered cmeABC promoter
mutants.
From the cmeABC promoter mutants, 6 representative sequences were selected for analysis
by EMSA and transcriptional fusion (Fig 2A). The promoters from the isolates X7199 and
CT9:20 were selected for their unique deletions. The M32506 and CT3:7 promoters both con-
tain the A to G mutation at position 14, while the CT3:7 promoter also contains the 81–176
variation. The CT1:1 and CT1:9 promoters carry the G to A mutation at position 2.
The ability of CmeR to bind to the mutant cmeABC promoter sequences was assessed by
EMSA. The selected mutant cmeABC promoter sequences from clinical isolates were paired
with either the 11168 promoter (from strain NCTC 11168) (Fig 2B, panels I to III, lanes 1 to 4)
or 81–176 promoter (Fig 2B, panels IV to VI, lanes 1 to 4) for use in EMSA based on the pres-
ence or absence of the A to T 81–176 variation in the CmeR binding site. Five of the 6 mutant
promoters, CT1:1, CT1:9, M23506, CT3:7, and CT9:20 (Fig 2B, panels I, II, III, V, and VI
respectively, lanes 5 to 8) showed decreased binding to rCmeRSS as manifested by the
increased amounts of unbound probe and/or decreased amounts of probe- rCmeRSS com-
plexes. Specifically, the CT1:1 (Fig 2B, panel I, lanes 5 to 8), CT1:9 (Fig 2B, panel II, lane 5 to 8)
promoters showed increased amounts of free probe. The M32506 (Fig 2B, panel III, lane 5 to
8), CT3:7 (Fig 2B, panel V, lane 5 to 8), and CT9:20 (Fig 2B, panel VI, lane 5 to 8) probes dis-
play decreased intensity in the CmeR-DNA complexes and increased amounts of free probe.
The CT9:20 cmeABC promoter (Fig 2B, panel VI, lanes 5–8) showed the largest reduction in
CmeR binding (Fig 2B, panel VI lanes 7–8). The X7199 promoter displayed no difference in
binding to rCmeRSS compared to the 81–176 promoter (Fig 2B, panel IV). These results sug-
gest that most of the examined mutations in the cmeABC promoter sequence affected binding
by CmeR.
To further quantify the effect of the promoter mutations on cmeABC expression, transcrip-
tional fusion of the mutant cmeABC promoters to the promoterless lacZ gene was performed
in the presence and absence of CmeR. In the 81–176 wild-type background, CmeR is expressed
and binds to the cmeABC promoter, repressing its transcription. The 81–176ΔcmeR strain is an
isogenic mutant that does not express CmeR, resulting in a loss of repression for the cmeABC
promoter. Without this repressor, cmeABC is overexpressed. Transcription from the 11168
promoter in the 81–176 wild-type background (CmeR is present) was defined as the basal level
of cmeABC transcription and used as a control. In the presence of CmeR (81–176 wild-type
background) (Fig 3A), all examined cmeABC promoters were transcribed. Compared with the
base (11168 promoter), expression from the 81–176 promoter, CT1:1 promoter, CT1:9 pro-
moter, CT3:7 promoter, M32506 promoter, X7199 promoter was 2.4-fold (p = 0.0096),
4.6-fold (p = 0.0232), 5.5-fold (p = 0.0073), 5.6-fold (p = 0.0425), 6.3-fold (p = 0.0036), and
5.4-fold (p = 0.0150) higher, respectively. These increases are indicative of decreased repression
by CmeR due to the mutations in the cmeABC promoters. Notably, the CT9:20 promoter with
the deletion of the last 3 bases of the CmeR binding site, had the highest increase in transcrip-
tion at 8-fold (p = 0.0208) over the basal levels, consistent with its most obvious reduction in
binding by CmeR on EMSA.
Transcription from the CT1:1 and CT1:9 promoters, which had the same sequence (Fig 2A)
but was carried in different isolates, was not significantly different when compared to each
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Fig 3. Effect of various mutations in CmeR and the promoter region on transcription of cmeABC. The
names of the promoters used in the transcriptional fusions and β-galactosidase assays are indicated under
each panel. Each promoter was assayed in the wild-type 81–176 background (A) and the 81–176ΔcmeR
background (B). The data represent means with standard deviation from three independent experiments. The
relative difference in transcription (fold change) due to repression by CmeR for each promoter is shown in (C)
and was determined by comparison of transcription in the absence of CmeR (B) to the presence of CmeR (A).
The unpaired Student’s t-test with Welch’s correction was used for comparison of the means with significance
set at 0.05.
doi:10.1371/journal.pone.0131534.g003
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other. This indicates that choosing a single representative isolate is sufficient to evaluate the
other isolates in the group. The transcription from the X7199 and CT3:7 promoters, which had
the same two point mutations in the CmeR-binding site (Fig 2A), was not significantly differ-
ent between the two promoters, although there was an additional mutation (5-base pair dele-
tion) upstream of the CmeR binding site in the X7199 promoter. These results suggest that the
substitutions in the CmeR binding site alone (represented by CT3:7) is sufficient to alter
expression of cmeABC.
In the absence of CmeR, transcription for the 11168 and 81–176 promoters were elevated,
and the levels of transcription among the promoters except X7199 were not significantly differ-
ent (p> 0.05) (Fig 3B). Comparisons for each promoter in the presence (WT) and absence
(ΔcmeR) of CmeR showed that deletion of CmeR significantly increased expression (p<0.05)
of the cmeABC promoters from 11186 and 81–176 (Fig 3C). Transcription in the absence of
CmeR (81–176 ΔcmeR background) showed a 6.3-fold increase for the 11168 promoter
(p = 0.014), a 2.5-fold increase for the 81–176 promoter (p = 0.0039), and a 2.6-fold increase
for the X7199 promoter (p = 0.0367) (Fig 3C). The smaller change for the 81–176 and X7199
promoters compared to the 11168 promoter is likely due to already elevated expression in the
wild-type background mediated by the CmeR binding site mutations (Fig 3A). Compared to
their transcription in the cmeR wild-type background, the expression of CT1:1, CT1:9, CT3:7,
M32506, and CT9:20 promoters were not significantly different (p> 0.05), suggesting that
inactivation of cmeR did not further increase transcription from these promoters (Fig 3C).
Varied expression levels of cmeR in clinical isolates
Several DNA polymorphisms were detected in the cmeR gene of the clinical isolates, resulting
in amino acid changes in this regulatory protein (Table 3). Immunoblotting of whole cell pro-
teins was performed to determine the CmeR expression level from 8 OEL isolates and 1 WEL
isolate harboring representative mutations. The anti-CmeR antibody detected the CmeR pro-
tein from 8 of the 9 cmeRmutants (Fig 4A). The remaining cmeRmutant isolate (CT2:2) did
not produce a band reactive with the antibody (Fig 4B, lane 2), suggesting that the CmeR pro-
tein was not translated in this isolate. CT2:2 contained a T insertion after base 583 in cmeR,
resulting in a frame shift and premature truncation (Table 3). Additional immunoblotting
failed to detect any portion of the truncated CmeR from CT 2:2.
Fig 4. Expression of CmeR in various isolates and its correlation with CmeABC expression. (A)
Immunoblotting of whole cell proteins from NCTC 11168 (lane 1), clinical isolates (lanes 2–9), and
11168ΔcmeR (lane 10) with the anti-CmeR antibody. The clinical isolates in lanes 2 to 9 are M63885, CT9:7,
CB2:6, CB2:8, CB2:11, S13530, T37957A, and X7199, respectively. (B) Immunoblotting of whole cell
proteins from 11168ΔcmeR (lane 1), CT2:2 (lane 2), and NCTC 11168 (lanes 3) with anti-CmeR, anti-CmeB,
and anti-CmeA antibodies.
doi:10.1371/journal.pone.0131534.g004
Differential Expression of CmeABC
PLOSONE | DOI:10.1371/journal.pone.0131534 July 1, 2015 16 / 26
To confirm the results of immunoblotting, cmeR expression was evaluated by real time
RT-PCR. Real time expression levels of cmeR varied dramatically among the 9 isolates. Expres-
sion ranged from 0.006 to 33 fold of that in NCTC 11168 (Table 3), however this was not corre-
lated with CmeR expression levels on immunoblotting (S2 Table). The transcript level of cmeR
from CT2:2 were negligible at 0.006 fold of that in NCTC 11168, consistent with the lack of
protein expression as detected by immunoblotting (Fig 4).
cmeR and Cj0369c form a two-gene operon and share a single promoter located in front of
Cj0369c [13]. The predicted promoter for the Cj0369c-cmeR operon contains an inverted repeat
with two half sites separated by a 12-base spacer that may represent an unknown regulatory
mechanism [13]. Sequence analysis of this region was performed on several isolates to deter-
mine if mutations occurred and if they could be correlated with the varying cmeR expression
levels identified by real time RT-PCR. Mutations of the Cj0369c-cmeR promoter were found in
some isolates after comparison to the sequence of NCTC 11168 and were divided into 2 groups
(S2 Table). The first group carried a single base deletion one base 5’ to the second half site of
the inverted repeat in strains 81–176, T37957A, and E46972. The second group, consisting of
isolates X7199, W52546, and S13530, contained a T insertion in the second half site of the
inverted repeat after the eighth base and a G to A substitution at base 5 of the spacer. The
Cj0369c-cmeR promoter from CT2:2 had no mutations, suggesting that transcription from this
promoter is unlikely the source of the decreased production as observed by immunoblotting
and real-time PCR.
Transcriptional fusion of representative Cj0369c-cmeR promoters from strains 81–176,
X7199, and NCTC 11168 was performed to determine if the observed polymorphisms affected
transcription. The 81–176, NCTC 11168, and X7199 promoters produced low levels of tran-
scription (mean Miller units in the range of 8–15), which were not significantly different
(p> 0.05) (S1 Fig), suggesting that these mutations were not associated with the expression
levels of cmeR. However, this was not consistent with the real time cmeR expression data
(Table 3). The mutations observed in the Cj0369c-cmeR promoter for X7199 and the S13530
were identical but, cmeR expression was 10.9 and 0.2 fold of NCTC 11168 respectively. The rea-
son for this discrepancy is unclear.
Truncation, but not amino acid substitution affected CmeR binding to the
cmeABC promoter
The amino acid changes in CmeR observed in clinical isolates were categorized into 5 groups
represented by the 9 cmeRmutant isolates (Table 3). Site-directed mutagenesis and recombi-
nant CmeR production were performed for 3 representative isolates with amino acid substitu-
tions and a single isolate with substitution and truncation of CmeR (Table 3). The 4 proteins
produced were named rCmeR-tr, rCmeR-IK, rCmeR-K and rCmeR-R. The rCmeR-IK from
M63885 contains 2 amino acid substitutions at residues 6 and 159 replacing threonine with iso-
leucine and glutamate with lysine, respectively. The rCmeR-K from T37957A and rCmeR-R
from CT9:7 contain single amino acid substitutions of the glutamate at residue 84 for lysine in
rCmeR-K and the proline 183 residue for arginine in rCmeR-R. The rCmeR-tr from isolate
CT2:2 contains a glycine to alanine substitution at residue 144 and a nucleotide insertion after
base 583 resulting in pre-mature truncation of CmeR to 193 amino acids (the full-length CmeR
is 210 amino acids). The S207G substitution observed in CT2:2 occurs downstream of the trun-
cation and was not expected to affect CmeR function. rCmeR-tr was detected by immunoblot-
ting with the anti-CmeR antibody and presented as a band of 23 kD (Fig 5A, lane 3), slightly
smaller than the full-length rCmeRSS at 24kD (Fig 5A, lane 2), consistent with the predicted
truncation.
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EMSA was performed with all 4 mutant proteins to assess the binding to the NCTC 11168
cmeABC promoter (11168 promoter). The rCmeR-R, rCmeR-IK, or rCmeR-K proteins bound
to the cmeABC promoter in a manner similar to the rCmeRSS control (S2 Fig). However,
rCmeR-tr failed to bind to the cmeABC promoter at all tested concentrations (Fig 5B, lanes
5–8) suggesting that the truncation abolished the ability to bind promoter DNA.
Differences in antimicrobial susceptibility
In vitro antimicrobial susceptibilities did not differ between the OEL and WEL isolates in the
presence or absence of bile for most of the tested antimicrobials except for chloramphenicol.
Without bile, the median MIC for chloramphenicol was 4 μg/mL for both the OEL and WEL
isolates (Table 4). However, the distribution of MICs around the median was significantly dif-
ferent between the two phenotypic groups (p< 0.05). The WEL isolates had chloramphenicol
MICs of 2 to 4 μg/mL with 67% of the isolates at 4 μg/ml, while the OEL isolates had MICs
ranging from 2 to 16 μg/mL with 21% of the isolates at 8 and 16 μg/mL (Table 4). With bile in
the testing media, the MIC distribution between the two phenotypes was also significantly dif-
ferent (p<0.05) (Table 4). Although the median remains at 4 μg/mL for both groups, 81% of
the OEL isolates were at this MIC, while 58% of the WEL isolate were at this MIC. Both OEL
andWEL isolates have MIC ranges of 2 to 8 μg/mL after addition of bile. Compared to the
Fig 5. Inability of recombinant CmeR from isolate CT2:2 to bind to the promoter DNA of cmeABC. (A) Immunoblotting of purified rCmeRSS (lane 2;
wild-type CmeRwith C69 and C166 replaced with serine) and rCmeR-tr (lane 3; truncated CmeR after residue 193 from isolate CT2:2) with the anti-CmeR
antibody. Lane 1 is the protein standard ladder. (B) EMSA showing binding of the 11168 cmeABC promoter by rCmeRSS (lanes 1–4) and rCmeR-tr (lanes
5–8). Proteins were added at 0, 60 (lanes 2 and 6), 120 (lanes 3 and 7), 180 ng (lanes 4 and 8). The locations of protein-DNA complexes and the probe are
indicated.
doi:10.1371/journal.pone.0131534.g005
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non-bile media, addition of bile shifted the MIC to the upper end for WEL isolates and shifted
the MIC to the median the for OEL isolates.
Emergence of ciprofloxacin-resistant mutants
The spontaneous mutation rate to ciprofloxacin was examined for selected isolates using the
fluctuation assay. Although there was a trend that the mutation rate was higher in OEL than in
WEL, the difference was not statistically significant (p> 0.05) (S3 Fig). However, OEL isolates
showed increased emergence of ciprofloxacin-resistant (CipR) mutants during in vitro treat-
ment (Fig 6). Two experiments were performed with the initial inoculum levels of 107 and 106
CFU/mL, respectively. For the inoculums at 107 CFU/mL, there were no significant difference
in the mean numbers of pre-existing CipR mutants between the WEL and OEL cultures on day
0 (Fig 6A). CipR populations from both WEL and OEL cultures expanded over days 1 to 3. The
mean CipR mutant populations were 0.9 logs higher for OEL on day 1, 1.5 logs higher on day 2,
and 2 logs higher thanWEL on day 3. However, the means were not significantly different
between the OEL and WEL groups (p> 0.05).
For the inoculum of 106 CFU/mL, the means for pre-existing CipR mutants on day 0 were
not significantly different for the WEL and OEL cultures. The mean CipR mutant numbers on
day 1 were 2 logs (p = 0.0175) higher than the mutants in the WEL cultures. This trend contin-
ued on days 2 and 3 with OEL means being 3.7 logs (p = 0.0053) and 4.2 logs (p = 0.0016)
higher than the WEL means, respectively. These results indicate OEL cultures produced signifi-
cantly higher numbers of CipR mutants than the WEL cultures during ciprofloxacin treatment.
Discussion
This study demonstrates that differential expression of CmeABC naturally occurs in Campylo-
bacter isolates derived from different host species. The variable expression was linked to multi-
ple mechanisms including mutations in the cmeABC promoter region and coding sequences of
CmeR as well as decreased expression of CmeR, the repressor for the cmeABC operon. Addi-
tionally, there are unidentified mechanisms that also modulate cmeABC expression as some
OEL isolates did not have any mutations in the known regulatory elements for cmeABC. Differ-
ential expression of cmeABC was associated with altered susceptibility to chloramphenicol and
enhanced the emergence of CipR mutants under selection with ciprofloxacin. These findings
suggest that differential expression of CmeABC may be selected under natural conditions and
may facilitate Campylobacter adaptation to various environments.
Of the 64 isolates examined in this study, 43 (67%) were phenotypically classified as OEL
isolates. CmeABC is normally repressed by CmeR, which binds to the promoter region of
cmeABC [12]. Thus, mutations in CmeR and/or the cmeABC promoter sequence were
Table 4. Chloramphenicol MIC distribution (% for each MIC) among the tested isolates.
MIC 2 μg/mL 4 μg/mL 8 μg/mL 16 μg/mL
MH agar
WEL 33 67 0 0
OEL 42 37 19 2
MH agar with ox-bile1
WEL 33 58 8 0
OEL 16 81 2 0
1Ox bile 12,500 μg/mL
doi:10.1371/journal.pone.0131534.t004
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investigated to determine the genetic basis associated with overexpression of cmeABC in these
clinical isolates. Those mutations that occurred in the CmeR binding site or resulted in amino
acid changes in CmeR and were absent from the majority of the WEL isolates were selected for
detailed analysis. Additionally, those isolates harboring the same mutation as the one in the
Fig 6. Emergence of ciprofloxacin-resistant mutants fromWEL (circle) and OEL (triangle) isolates
during treatment with ciprofloxacin. In panel A, the experiment was performed with an initial inoculum of
107 CFU/ml of each isolate, while in panel B, the inoculum was 106 CFU/mL for each isolate. The culture
medium was MH broth containing 4 μg/mL of ciprofloxacin. ThreeWEL and OEL isolates were used in each
experiment with cultures prepared in triplicate. Each point represents the number of ciprofloxacin-resistant
mutants from a single culture. Bars represent mean log10 CFU/mL for each group. Means for each phenotypic
group were compared for each day with multiple unpaired Student’ t-tests and Holm-Šídák method for
multiple comparisons. The significance level was set at 0.05.
doi:10.1371/journal.pone.0131534.g006
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CmeR binding site of strain 81–176 were excluded from analysis as this mutation has been
characterized previously [12]. Using these selection criteria, we selected 14 isolates harboring
promoter mutations and 9 isolates harboring CmeR mutations for detailed analysis.
Most of the detected amino acid substitutions in CmeR did not affect its function as deter-
mined by EMSA. However, a single nucleotide insertion at the 3’end of the cmeR gene resulted
in a frame-shift and presumably led to truncation of the CmeR protein in CT2:2. CmeR was
not detected by immunoblotting in CT2:2 (Fig 4B) and the cmeR transcript level was also sig-
nificantly reduced. Additionally, CT2:2 did not contain any mutations in the predicted
Cj0369c-cmeR promoter region, excluding the possibility that lack of cmeR expression was due
to altered transcription initiation. These findings suggest that the single nucleotide insertion
could have destabilized the cmeR transcript and/or the frame shift rendered the CmeR protein
unstable in C. jejuni, leading to the lack of CmeR in this isolate. However, a recombinant ver-
sion of the truncated CmeR (rCmeR-tr) was successfully generated (Fig 5A), suggesting that
this truncated CmeR is stable in the E. coli host. Interestingly, rCmeR-tr failed to bind to the
promoter DNA of cmeABC as determined by EMSA (Fig 5B), suggesting that even if this trun-
cated version is made in C. jejuni, it would not be able to control the expression of cmeABC.
The lack of CmeR production and the inability of the truncated CmeR to bind to promoter
DNA fully explain the overexpression of cmeABC in isolate CT2:2.
It is interesting that rCmeR-tr lost the ability to bind DNA despite the fact that the trunca-
tion occurred in the C-terminal end of CmeR and the DNA-binding domain remained intact.
This could be explained using the known structural information of CmeR. CmeR functions as
dimer in vivo and the crystal structure of CmeR identified that α helices 6, 8, 9, and 10 are
involved in dimer formation [12, 15, 50]. The truncation in rCmeR-tr occurred in the α10
helix of CmeR. Thus, the truncation in rCmeR-tr likely affects dimer formation and ultimately
the function of CmeR. This result suggests that the C-terminal sequence of CmeR is also
important for its interaction with target DNA. Recently, C. jejuni ATCC 33560, a quality con-
trol strain used for antimicrobial susceptibility testing in C. jejuni, was found to contain a
frame shift mutation in cmeR, which led to truncation of the CmeR protein [51]. The trunca-
tion occurs in α helix 8 of CmeR and presumably results in non-functional CmeR [51].
Together, these findings indicate that frame-shift mutations in CmeR occur under natural con-
ditions. As CmeR is a pleiotropic regulator (regulating other genes in addition to cmeABC)
[13], truncation of CmeR likely affects multiple functions in C. jejuni.
The majority of the mutations in the cmeABC promoter were found to affect cmeABC
expression. The cmeABC promoter contains a 16 base inverted repeat that serves as the specific
binding site for CmeR [12]. Mutations in the CmeR binding site within the cmeABC promoter
have been described previously after in vitro stepwise selection with erythromycin [14] and cip-
rofloxacin [12]. This study is the first to describe the occurrence of this type of mutation in C.
jejuni isolates from natural sources and various hosts including humans, turkeys, and chickens.
These mutations inhibited binding by CmeR, resulting in increased transcription from the
cmeABC promoter. This was demonstrated by reduced binding of the mutant promoters by
CmeR on EMSA (Fig 2B, panels I, II, III,V, and VI) and increased transcription of cmeABC as
determined by transcriptional fusion assays (Fig 3). In addition to the substitution, deletions
within the CmeR binding site were found in one isolate, CT9:20. This promoter showed the
greatest inhibition of CmeR binding on EMSA and the largest increase in transcription in the
presence of CmeR (Fig 3A). These findings indicate that mutations in the cmeABC promoter
commonly occur and these mutations influence the expression of this multidrug efflux pump.
Multiple mutations were also identified in a single isolate. For example, isolate X7199 har-
bored a substitution in the CmeR binding site and a 5 base deletion upstream of the CmeR
binding site (Fig 2A). This isolate also contained mutations in cmeR (Table 3). The cmeABC
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promoter in this isolate was identical to the promoter in CT3:7 except for a 5-base pair deletion
upstream of the CmeR binding site (Fig 2A). While the CT3:7 promoter demonstrated reduced
binding to CmeR on EMSA (Fig 2B, panel V), the X7199 promoter had similar binding as the
81–176 cmeABC promoter (Fig 2B, panel IV). However, both the X7199 and CT3:7 cmeABC
promoters demonstrated similar, elevated expression by transcriptional fusion assay compared
with the 11168 promoter in the presence of CmeR (Fig 3A). This discrepancy between the
results of EMSA and transcriptional fusion suggests that the EMSA assay has a lower sensitivity
than the transcriptional fusion assay, or alternatively, there is another regulatory mechanism
that also modulates cmeABC expression. Indeed, when the X7199 promoter was examined in
the absence of CmeR using transcriptional fusion (Fig 3B), its expression was significantly
increased compared to its own expression level in the presence of CmeR (Fig 3C). This result is
consistent with the EMSA result and suggests that the X7199 promoter is still under the repres-
sion by CmeR.
In some isolates, the OEL phenotype was not linked to the known mechanisms modulating
cmeABC expression as there were no mutations detected in CmeR or the promoter region.
Additionally, even though some isolates harbored mutations in CmeR, these mutations did not
affect the function of CmeR. Furthermore, the regulation of the X7199 promoter cannot be
fully explained by a CmeR-only-dependent mechanism. These findings suggest that there may
be additional regulatory mechanisms modulating cmeABC expression. Previously, Lin et. al.
2005 also described a CmeR-independent mechanism modulating cmeABC expression [16].
Bile is a known inducer of CmeABC and mediates increased expression by altering the confir-
mation of CmeR, resulting in disassociation of CmeR from the cmeABC promoter [15, 16]. It
was noticed that in the absence of CmeR, the expression of cmeABC was further induced by
taurocholate, suggesting this bile compound induced expression of cmeABC through a CmeR-
independent mechanism [16]. Taken together, observations from this study and previous
reports suggest that multiple mechanisms modulate the expression of cmeABC.
`The functional consequence of cmeABC overexpression was evaluated in relation to antimi-
crobial treatments. Antimicrobial susceptibility was unaffected by cmeABC overexpression for
most of the tested antibiotics, with the exception of chloramphenicol. This was not surprising as
a previous study using genetic manipulation revealed that overexpressing cmeABC by inactivat-
ing cmeR had a modest effect on MICs, but inactivation of cmeABC significantly increased the
susceptibility of C. jejuni to antibiotics [6, 12]. For chloramphenicol, the OEL isolates displayed a
larger range of MIC values thanWEL isolates, with more MICs distributed above the median
value (Table 4). This suggests that overexpression of CmeABC had an effect on the MIC distri-
bution of chloramphenicol. Interestingly, when chloramphenicol MIC was measured in the pres-
ence of bile, the MICs of the WEL isolates shifted above the median value, while the MICs of the
OEL isolates shifted toward the median value. This difference is probably due to the fact that bile
is an inducer for cmeABC and the possibility that induction was more prominent in the WEL
isolates than in the OEL isolates. For the OEL isolates, cmeABCwas already overexpressed due
to less inhibition by CmeR or other unidentified mechanisms. Thus, the bile-mediated induction
through CmeR is expected to be less effective in the OEL isolates than in theWEL isolates.
Fluoroquinolones resistance in Campylobacter is mediated by DNA gyrase mutations and
the function of CmeABC [6, 8, 9]. These two mechanisms function synergistically in mediating
resistance to fluoroquinolones [9]. Additionally, CmeABC promotes the emergence of fluoro-
quinolone-resistant mutants under antibiotic selection [8, 23]. In this study, we examined the
correlation between the OEL phenotype and ciprofloxacin resistance. It was found that the
basal spontaneous mutation rate was not affected by overexpression of cmeABC as measured
by the fluctuation assay. However, the OEL isolates showed higher level of emergence of CipR
mutants under antibiotic selection (Fig 6). This was consistently shown by using two
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inoculation doses (106 and 107 CFU/mL). For the 107 CFU/mL inoculum, the difference
between the OEL and WEL groups were obvious, but were not statistically significant. For the
106 CFU/mL inoculum, the numbers of CipR mutants from the OEL isolates were significantly
higher than those from the WEL mutants. The lack of statistical significance with the 107
CFU/mL inoculum was probably due to the presence of pre-existing CipR mutants in the inoc-
ulum (Fig 6) that somewhat reduced the difference between the OEL and WEL groups. Thus,
reducing the inoculum to 106 CFU/mL allowed clear detection of differences between the two
groups. These results suggest that the OEL phenotype may facilitate Campylobacter to adapt to
fluoroquinolone treatment by promoting the emergence of resistant mutants. This finding has
practical implication as fluoroquinolone antibiotics are used for both human medicine and ani-
mal production. Thus, the detection of a large number of C. jejuni with an OEL phenotype
from different host species might be the result of antibiotic usage that has served as a selection
force for the OEL phenotype.
In summary, this study reveals that overexpression of CmeABC commonly occurs in C.
jejuni isolates derived from various host species. The overexpression is mediated by multiple
mechanisms including mutations in the cmeABC promoter sequence and in the CmeR coding
sequence. Additionally, results from this study suggest that there are other unidentified mecha-
nisms that modulate the expression of CmeABC. Overexpression of cmeABC promotes the
development of resistant mutants upon treatment with fluoroquinolone antibiotics and may
contribute to the survival and persistence of C. jejuni in animal reservoirs where antibiotics are
commonly used. These findings provide new insights into the adaptive mechanisms of C. jejuni
and further highlight the potential to control antibiotic resistant Campylobacter by targeting
CmeABC.
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